Rifaximin: An Option for the Treatment of Irritable Bowel Syndrome
Objective: To study the response of irritable bowel syndrome patients presenting with diarrhea and abdominal pain to the treatment with Rifaximin. Study Design: Observational descriptive study. Place and Duration of Study: Study was carried out from 1st February 2019 to 1st December 2019 at Ga...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Riphah International University, Islamabad
2021-12-01
|
| Series: | Journal of Islamic International Medical College |
| Subjects: | |
| Online Access: | https://journals.riphah.edu.pk/index.php/jiimc/article/view/1168 |
| _version_ | 1798030882638921728 |
|---|---|
| author | Muhammad Abdul Quddus , Arslan Shahzad , Rukhsana Munawar , Khawaja Tahir Maqbool , Amna Mansoor , Naveed Gani , Sheikh Muhammad Taqqi Anwer |
| author_facet | Muhammad Abdul Quddus , Arslan Shahzad , Rukhsana Munawar , Khawaja Tahir Maqbool , Amna Mansoor , Naveed Gani , Sheikh Muhammad Taqqi Anwer |
| author_sort | Muhammad Abdul Quddus , Arslan Shahzad , Rukhsana Munawar , Khawaja Tahir Maqbool , Amna Mansoor , Naveed Gani , Sheikh Muhammad Taqqi Anwer |
| collection | DOAJ |
| description | Objective: To study the response of irritable bowel syndrome patients presenting with diarrhea and abdominal pain to the treatment with Rifaximin.
Study Design: Observational descriptive study.
Place and Duration of Study: Study was carried out from 1st February 2019 to 1st December 2019 at Gastroenterology department of Combined Military Hospital Rawalakot.
Materials and Methods: Total of 113 patients were consecutively chosen from the Gastroenterology Outpatient Department, Sheikh Khalifa Bin Zayed Al Nahyan Hospital/ AK Combined Military Hospital Rawalakot. Irritable bowel syndrome, diarrhea was diagnosed using Rome III criteria. All participants received 550 mg Rifaximin in two divided doses for a period of fourteen days and were observed for six weeks. The assessed symptoms were diarrhea and abdominal pain, which were recorded at baseline and then at 6 week follow up. Descriptive statistics were done to look for the response of patients’ clinical symptoms to Rifaximin.
Results: Mean age of the participants was 26.96 years. Out of 113 subjects, 45% were male (51/113) and 55% (62/113) females. Rifaximin was found to be effective in relieving symptoms in 99(87.6%) cases while it did not relieve symptoms in 14 (12.4%) cases. Only 14(12.4%) patients developed headache as a side effect, while the rest 99(87.6%) tolerated it well.
Conclusion: Rifaximin is a useful, effective and a safe drug for the treatment of irritable bowel syndrome patients suffering from diarrhea and abdominal pain. |
| first_indexed | 2024-04-11T19:48:25Z |
| format | Article |
| id | doaj.art-bdaff5b75b64487094b8a67f3d4b5dfd |
| institution | Directory Open Access Journal |
| issn | 1815-4018 2410-5422 |
| language | English |
| last_indexed | 2024-04-11T19:48:25Z |
| publishDate | 2021-12-01 |
| publisher | Riphah International University, Islamabad |
| record_format | Article |
| series | Journal of Islamic International Medical College |
| spelling | doaj.art-bdaff5b75b64487094b8a67f3d4b5dfd2022-12-22T04:06:23ZengRiphah International University, IslamabadJournal of Islamic International Medical College1815-40182410-54222021-12-011642152181564Rifaximin: An Option for the Treatment of Irritable Bowel SyndromeMuhammad Abdul Quddus , Arslan Shahzad , Rukhsana Munawar , Khawaja Tahir Maqbool , Amna Mansoor , Naveed Gani , Sheikh Muhammad Taqqi AnwerObjective: To study the response of irritable bowel syndrome patients presenting with diarrhea and abdominal pain to the treatment with Rifaximin. Study Design: Observational descriptive study. Place and Duration of Study: Study was carried out from 1st February 2019 to 1st December 2019 at Gastroenterology department of Combined Military Hospital Rawalakot. Materials and Methods: Total of 113 patients were consecutively chosen from the Gastroenterology Outpatient Department, Sheikh Khalifa Bin Zayed Al Nahyan Hospital/ AK Combined Military Hospital Rawalakot. Irritable bowel syndrome, diarrhea was diagnosed using Rome III criteria. All participants received 550 mg Rifaximin in two divided doses for a period of fourteen days and were observed for six weeks. The assessed symptoms were diarrhea and abdominal pain, which were recorded at baseline and then at 6 week follow up. Descriptive statistics were done to look for the response of patients’ clinical symptoms to Rifaximin. Results: Mean age of the participants was 26.96 years. Out of 113 subjects, 45% were male (51/113) and 55% (62/113) females. Rifaximin was found to be effective in relieving symptoms in 99(87.6%) cases while it did not relieve symptoms in 14 (12.4%) cases. Only 14(12.4%) patients developed headache as a side effect, while the rest 99(87.6%) tolerated it well. Conclusion: Rifaximin is a useful, effective and a safe drug for the treatment of irritable bowel syndrome patients suffering from diarrhea and abdominal pain.https://journals.riphah.edu.pk/index.php/jiimc/article/view/1168abdominal pain, diarrhea, irritable bowel syndrome, rifaximin. |
| spellingShingle | Muhammad Abdul Quddus , Arslan Shahzad , Rukhsana Munawar , Khawaja Tahir Maqbool , Amna Mansoor , Naveed Gani , Sheikh Muhammad Taqqi Anwer Rifaximin: An Option for the Treatment of Irritable Bowel Syndrome Journal of Islamic International Medical College abdominal pain, diarrhea, irritable bowel syndrome, rifaximin. |
| title | Rifaximin: An Option for the Treatment of Irritable Bowel Syndrome |
| title_full | Rifaximin: An Option for the Treatment of Irritable Bowel Syndrome |
| title_fullStr | Rifaximin: An Option for the Treatment of Irritable Bowel Syndrome |
| title_full_unstemmed | Rifaximin: An Option for the Treatment of Irritable Bowel Syndrome |
| title_short | Rifaximin: An Option for the Treatment of Irritable Bowel Syndrome |
| title_sort | rifaximin an option for the treatment of irritable bowel syndrome |
| topic | abdominal pain, diarrhea, irritable bowel syndrome, rifaximin. |
| url | https://journals.riphah.edu.pk/index.php/jiimc/article/view/1168 |
| work_keys_str_mv | AT muhammadabdulquddusarslanshahzadrukhsanamunawarkhawajatahirmaqboolamnamansoornaveedganisheikhmuhammadtaqqianwer rifaximinanoptionforthetreatmentofirritablebowelsyndrome |